Email ID
Password
Scrip   
Novartis licenses potential new hepatitis C treatment from Debiopharm
09 February 2010
Sukaina Virji

Novartis has licensed exclusive rights to develop and market Debiopharm's Debio 025 (alisporivir), which is currently in Phase IIb testing for the treatment of hepatitis C.

Financial terms have not been disclosed, but the deal includes an upfront payment to Debiopharm, an independent Swiss...



Please Login to read the full article.
JOB OF THE WEEK Promote your vacancy here
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36